Introducing HeartFlow ONE
Introducing HeartFlow ONE
HeartFlow ONE is transforming precision heart care with the first, all-in-one-coronary care solution.
HeartFlow ONE is the only complete, non-invasive, precision coronary care solution throughout the guideline-directed CCTA pathway.
Backed by robust clinical evidence, clinicians can now see and gain a full understanding of anatomy, physiology and plaque – allowing them to evaluate and provide earlier, timesaving, life-altering care that is truly individualized.
HeartFlow is committed to building your CCTA program and delivering gold-standard, scalable heart care services and solutions.
Conventional methods are reactive and do not provide the most timely, complete or accurate information for assessing and managing patients for coronary artery disease (CAD).
Direct to Cath
Conventional methods are reactive and do not provide the most timeline, complete or accurate information for assessing and managing patients for coronary artery disease (CAD).
Direct to Cath
HeartFlow ONE is clinically proven to be the only non-invasive, fully integrated solution throughout the entire CCTA pathway.
HeartFlow is committed to building CCTA programs while delivering unparalleled, scalable heart care support and services.
Expert CT application specialists will assist your CT technologists with acquisition protocols and educate on best practices to develop a best-in-class CT program.
Support to deploy and configure software and integrate with PACS, EHR/EMR and other IT solutions seamlessly.
Includes ongoing security and software updates.
Includes HeartFlow’s Full Support and Expertise
Receive physician mentorship from other institutions who have implemented HeartFlow technologies.
Send in individual case feedback or questions with prompt engagement from our customer support team.
Let’s defeat heart disease one patient and one heart at a time.
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.
Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.